dc.contributor.author |
Finkelsztejn, A. |
|
dc.contributor.author |
Gabbai, A.A. |
|
dc.contributor.author |
Fragoso, Y.D. |
|
dc.contributor.author |
Carrá, A. |
|
dc.contributor.author |
Macías-Islas, M.A. |
|
dc.contributor.author |
Arcega-Revilla, R. |
|
dc.contributor.author |
García-Bonitto, J. |
|
dc.contributor.author |
Oehninger-Gatti, C.L. |
|
dc.contributor.author |
Orozco-Escobar, G. |
|
dc.contributor.author |
Tarulla, A. |
|
dc.contributor.author |
Vergara, F. |
|
dc.contributor.author |
Vizcarra-Escobar, Darwin |
|
dc.date.accessioned |
2022-01-18T19:34:40Z |
|
dc.date.available |
2022-01-18T19:34:40Z |
|
dc.date.issued |
2012 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/11124 |
|
dc.description.abstract |
Objective: It is estimated that circa 50,000 individuals have relapsing-remitting multiple sclerosis in Latin America. European and NorthAmerican algorithms for the treatment of multiple sclerosis do not foresee our regional difficulties and the access of patients to treatment. Methods: The Latin American Multiple Sclerosis Forum is an independent and supra-institutional group of experts that has assessed the latest scientific evidence regarding efficacy and safety of disease-modifying treatments. Accesses to treatment and pharmacovigilance programs for each of the eight countries represented at the Forum were also analyzed. Results: A specific set of guidelines based upon evidence-based recommendations was designed for Latin America. Future perspectives of multiple sclerosis treatment were also discussed. Conclusions: The present paper translated an effort from representatives of eight countries discussing a matter that cannot be adapted to our region directly from purely European and North-American guidelines for treatment. |
en_US |
dc.description.abstract |
OBJETIVO: Estima que haja aproximadamente 50.000 pessoas com a forma remitente-recorrente da esclerose múltipla na América Latina. Os algoritmos de tratamento norte-americanos e europeus não levam em consideração nossas peculiaridades regionais, nem a dificuldade no acesso ao tratamento por parte dos pacientes. MÉTODOS: O Fórum Latino-americano de Esclerose Múltipla é um grupo de especialistas independente e suprainstitucional, que avaliou as mais recentes evidências científicas sobre a eficácia e a segurança das drogas modificadoras do curso da doença. Foram avaliados também o acesso ao tratamento e os programas de farmacovigilância de cada um dos oito países representados no Fórum. RESULTADOS: Uma lista específica de recomendações baseadas em evidências científicas foi estabelecida para a América Latina. Também foram discutidas perspectivas de futuros tratamentos para esclerose múltipla. CONCLUSÕES: O presente estudo representou um esforço dos representantes de oito países latino-americanos em discutir um assunto que não pode ser adaptado para uso em nossa região diretamente a partir de recomendações de tratamento europeias ou norte-americanas. |
pt_BR |
dc.language.iso |
eng |
|
dc.publisher |
SP Academia Brasileira de Neurologia |
|
dc.relation.ispartofseries |
Arquivos de Neuro-Psiquiatria |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
Brazil |
en_US |
dc.subject |
Latin America |
en_US |
dc.subject |
South and Central America |
en_US |
dc.subject |
azathioprine |
en_US |
dc.subject |
cyclophosphamide |
en_US |
dc.subject |
drug efficacy |
en_US |
dc.subject |
drug megadose |
en_US |
dc.subject |
hematologic disease |
en_US |
dc.subject |
infection |
en_US |
dc.subject |
low drug dose |
en_US |
dc.subject |
methotrexate |
en_US |
dc.subject |
randomized controlled trial (topic) |
en_US |
dc.subject |
rituximab |
en_US |
dc.subject |
disease course |
en_US |
dc.subject |
treatment outcome |
en_US |
dc.subject |
sepsis |
en_US |
dc.subject |
virus detection |
en_US |
dc.subject |
algorithm |
en_US |
dc.subject |
drug safety |
en_US |
dc.subject |
pregnancy |
en_US |
dc.subject |
alemtuzumab |
en_US |
dc.subject |
alopecia |
en_US |
dc.subject |
amenorrhea |
en_US |
dc.subject |
Argentina |
en_US |
dc.subject |
atrioventricular block |
en_US |
dc.subject |
beta interferon |
en_US |
dc.subject |
blood cell count |
en_US |
dc.subject |
bradycardia |
en_US |
dc.subject |
brain atrophy |
en_US |
dc.subject |
cardiotoxicity |
en_US |
dc.subject |
clinical trial (topic) |
en_US |
dc.subject |
cystitis |
en_US |
dc.subject |
drug approval |
en_US |
dc.subject |
drug surveillance program |
en_US |
dc.subject |
Expanded Disability Status Scale |
en_US |
dc.subject |
fingolimod |
en_US |
dc.subject |
gadolinium |
en_US |
dc.subject |
glatiramer |
en_US |
dc.subject |
hyperthyroidism |
en_US |
dc.subject |
hypothyroidism |
en_US |
dc.subject |
leukemia |
en_US |
dc.subject |
medical decision making |
en_US |
dc.subject |
methylprednisolone |
en_US |
dc.subject |
mitoxantrone |
en_US |
dc.subject |
Multiple sclerosis |
en_US |
dc.subject |
natalizumab |
en_US |
dc.subject |
neurologist |
en_US |
dc.subject |
nuclear magnetic resonance |
en_US |
dc.subject |
phase 3 clinical trial (topic) |
en_US |
dc.subject |
progressive multifocal leukoencephalopathy |
en_US |
dc.subject |
retina macula edema |
en_US |
dc.subject |
rheumatoid arthritis |
en_US |
dc.subject |
systematic review (topic) |
en_US |
dc.subject |
thrombocytopenic purpura |
en_US |
dc.subject |
thyroiditis |
en_US |
dc.subject |
Treatment |
en_US |
dc.subject |
unspecified side effect |
en_US |
dc.subject |
esclerose múltipla |
pt_BR |
dc.subject |
tratamento |
pt_BR |
dc.subject |
América Latina |
pt_BR |
dc.title |
Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents |
en_US |
dc.title.alternative |
Algoritmo latino-americano para tratamento da esclerose múltipla remitente-recorrente utilizando drogas modificadoras da doença |
es_PE |
dc.type |
info:eu-repo/semantics/review |
|
dc.identifier.doi |
https://doi.org/10.1590/S0004-282X2012001000009 |
|
dc.subject.ocde |
https://purl.org/pe-repo/ocde/ford#3.01.04 |
|
dc.relation.issn |
1678-4227 |
|